P

Assignee

CELLECTIS

FR80 patents

Top patents by PatentIndex Score

US9855297B2Jan 2, 2018

Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system

CELLECTIS50 citations97
US7842489B2Nov 30, 2010

Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof

CELLECTIS63 citations95
US9944702B2Apr 17, 2018

CD33 specific chimeric antigen receptors for cancer immunotherapy

CELLECTIS29 citations94
US9944709B2Apr 17, 2018

CD123 specific chimeric antigen receptors for cancer immunotherapy

CELLECTIS21 citations94
US9890393B2Feb 13, 2018

Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system

CELLECTIS38 citations94
US10584352B2Mar 10, 2020

Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system

CELLECTIS21 citations93
US10874693B2Dec 29, 2020

CD19 specific chimeric antigen receptor and uses thereof

CELLECTIS7 citations92
US10426795B2Oct 1, 2019

Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cells

CELLECTIS8 citations92
US10286007B2May 14, 2019

Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells

CELLECTIS12 citations92
US7897372B2Mar 1, 2011

I-CreI meganuclease variants with modified specificity, method of preparation and uses thereof

CELLECTIS42 citations91
US10836998B2Nov 17, 2020

Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells

CELLECTIS5 citations84
US10378026B2Aug 13, 2019

RNA based method to obtain stably integrated retroviral vectors

CELLECTIS6 citations84
US10316101B2Jun 11, 2019

BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy

CELLECTIS11 citations84
US10239948B2Mar 26, 2019

Method of engineering multi-input signal sensitive T cell for immunotherapy

CELLECTIS16 citations84
US10196608B2Feb 5, 2019

Method for in situ inhibition of regulatory T cells

CELLECTIS8 citations84
US10006052B2Jun 26, 2018

Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof

CELLECTIS17 citations84
US11274316B2Mar 15, 2022

Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells

CELLECTIS2 citations83
US11077144B2Aug 3, 2021

CD19 specific chimeric antigen receptor and uses thereof

CELLECTIS7 citations83
US10870864B2Dec 22, 2020

Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system

CELLECTIS4 citations83
US10752684B2Aug 25, 2020

ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy

CELLECTIS12 citations83
US10517896B2Dec 31, 2019

Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells

CELLECTIS2 citations83
US10363270B2Jul 30, 2019

Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapy

CELLECTIS6 citations83
US10759868B2Sep 1, 2020

Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy

CELLECTIS6 citations82
US10342829B2Jul 9, 2019

Multi-chain chimeric antigen receptor and uses thereof

CELLECTIS6 citations81
US8003595B2Aug 23, 2011

Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei

CELLECTIS7 citations78
US11014989B2May 25, 2021

Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy

CELLECTIS2 citations73
US10988541B2Apr 27, 2021

CD123 specific chimeric antigen receptors for cancer immunotherapy

CELLECTIS1 citations73
US10709775B2Jul 14, 2020

Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation

CELLECTIS7 citations73
US10472613B2Nov 12, 2019

Method for modulating car-induced immune cells activity

CELLECTIS6 citations73
US12577581B2Mar 17, 2026

Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells

CELLECTIS0 citations72
US11891614B2Feb 6, 2024

Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy

CELLECTIS1 citations72
US11466291B2Oct 11, 2022

Sequential gene editing in primary immune cells

CELLECTIS4 citations72
US11414674B2Aug 16, 2022

Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells

CELLECTIS0 citations72
US11304975B2Apr 19, 2022

Methods for engineering allogeneic and highly active t cell for immunotherapy

CELLECTIS4 citations72
US11186824B2Nov 30, 2021

Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients

CELLECTIS4 citations72
US10113162B2Oct 30, 2018

Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes

CELLECTIS6 citations69
US9365864B2Jun 14, 2016

Meganuclease recombination system

CELLECTIS3 citations69
US10087453B2Oct 2, 2018

Modified diatoms for biofuel production

CELLECTIS4 citations68
US11959091B2Apr 16, 2024

Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system

CELLECTIS0 citations62
US11919961B2Mar 5, 2024

CD123 specific chimeric antigen receptors for cancer immunotherapy

CELLECTIS0 citations62
US11692169B2Jul 4, 2023

Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells

CELLECTIS0 citations62
US11498971B2Nov 15, 2022

BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy

CELLECTIS1 citations62
US11365430B2Jun 21, 2022

Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system

CELLECTIS0 citations62
US11311575B2Apr 26, 2022

Methods for engineering highly active T cell for immunotherapy

CELLECTIS1 citations62
US11220683B2Jan 11, 2022

Method to overcome DNA chemical modifications sensitivity of engineered TALE DNA binding domains

CELLECTIS0 citations62
US11007224B2May 18, 2021

CD19 specific chimeric antigen receptor and uses thereof

CELLECTIS0 citations62
US10988542B2Apr 27, 2021

Chimeric antigen receptors with integrated controllable functions

CELLECTIS0 citations62
US10526406B2Jan 7, 2020

Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish

CELLECTIS1 citations62
US12391933B2Aug 19, 2025

Targeted gene insertion for improved immune cells therapy

CELLECTIS0 citations61
US12252699B2Mar 18, 2025

Method for generating t-cells compatible for allogenic transplantation

CELLECTIS0 citations61

Showing the top 50 of 80 patents by PatentIndex Score.